Total Payments
$10,240
2024 Payments
$1,813
Companies
38
Transactions
525
Medicare Patients
16,706
Medicare Billing
$2.9M
Payment Breakdown by Category
Food & Beverage$10,119 (98.8%)
Education$121.10 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,119 | 522 | 98.8% |
| Education | $121.10 | 3 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,542 | 113 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,956 | 115 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,106 | 59 | $0 (2024) |
| Mylan Specialty L.P. | $659.67 | 35 | $0 (2024) |
| GENZYME CORPORATION | $558.28 | 24 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $395.32 | 26 | $0 (2020) |
| Genentech USA, Inc. | $355.29 | 18 | $0 (2022) |
| JAZZ PHARMACEUTICALS INC. | $331.89 | 14 | $0 (2022) |
| Regeneron Healthcare Solutions, Inc. | $217.74 | 10 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $216.12 | 17 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,813 | 73 | AstraZeneca Pharmaceuticals LP ($436.33) |
| 2023 | $1,912 | 83 | GlaxoSmithKline, LLC. ($473.90) |
| 2022 | $1,098 | 60 | AstraZeneca Pharmaceuticals LP ($325.55) |
| 2021 | $1,048 | 68 | AstraZeneca Pharmaceuticals LP ($275.21) |
| 2020 | $807.65 | 41 | AstraZeneca Pharmaceuticals LP ($365.11) |
| 2019 | $1,359 | 72 | Sunovion Pharmaceuticals Inc. ($248.15) |
| 2018 | $1,178 | 67 | AstraZeneca Pharmaceuticals LP ($221.68) |
| 2017 | $1,024 | 61 | AstraZeneca Pharmaceuticals LP ($268.33) |
All Payment Transactions
525 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: RESPIRATORY | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $8.34 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $18.47 | General |
| Category: Medical Device | ||||||
| 11/27/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.63 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $2.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $47.57 | General |
| Category: Respiratory | ||||||
| 10/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/08/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $9.87 | General |
| Category: IMMUNOLOGY | ||||||
| 10/07/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 09/27/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: RESPIRATORY | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $1.39 | General |
| Category: RESPIRATORY | ||||||
| 09/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $34.92 | General |
| Category: RESPIRATORY | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: RESPIRATORY | ||||||
| 09/12/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Hyperkalemia | ||||||
| 09/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $3.11 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $30.14 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Respiratory | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: Respiratory | ||||||
| 08/20/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: Medical Device | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 3,572 | 13,478 | $2.6M | $560,255 |
| 2022 | 29 | 3,919 | 14,932 | $3.3M | $667,253 |
| 2021 | 32 | 4,449 | 16,756 | $2.9M | $834,816 |
| 2020 | 29 | 4,766 | 16,991 | $2.8M | $838,105 |
Total Patients
16,706
Total Services
62,157
Medicare Billing
$2.9M
Procedure Codes
119
All Medicare Procedures & Services
119 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 675 | 2,946 | $1.3M | $276,604 | 21.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 68 | 263 | $249,571 | $44,219 | 17.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 62 | 62 | $135,610 | $29,537 | 21.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 469 | 1,072 | $143,157 | $29,294 | 20.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 65 | 314 | $105,374 | $24,990 | 23.7% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 29 | 2,055 | $109,900 | $22,735 | 20.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 110 | 319 | $77,080 | $20,063 | 26.0% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 32 | 32 | $66,812 | $14,927 | 22.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 326 | 329 | $65,979 | $13,631 | 20.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 328 | 330 | $61,575 | $12,889 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $41,705 | $9,420 | 22.6% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 51 | 51 | $28,473 | $6,905 | 24.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 50 | $33,541 | $6,898 | 20.6% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 93 | 97 | $30,592 | $6,743 | 22.0% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 34 | 2,168 | $28,424 | $6,381 | 22.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 123 | 167 | $20,875 | $5,760 | 27.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 154 | 509 | $25,022 | $5,288 | 21.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 177 | 177 | $6,864 | $5,223 | 76.1% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 143 | 143 | $25,025 | $4,504 | 18.0% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 91 | 246 | $12,792 | $3,990 | 31.2% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 13 | 26 | $14,317 | $3,011 | 21.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 11 | 11 | $10,534 | $2,375 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 24 | $7,447 | $1,621 | 21.8% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 38 | 38 | $3,199 | $1,273 | 39.8% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 22 | 22 | $2,750 | $892.10 | 32.4% |
About Dr. Binusha Moitheennazima, MD
Dr. Binusha Moitheennazima, MD is a Pulmonary Disease healthcare provider based in Nacogdoches, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1760658330.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Binusha Moitheennazima, MD has received a total of $10,240 in payments from pharmaceutical and medical device companies, with $1,813 received in 2024. These payments were reported across 525 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($10,119).
As a Medicare-enrolled provider, Moitheennazima has provided services to 16,706 Medicare beneficiaries, totaling 62,157 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 119 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine, Sleep Medicine
- Location Nacogdoches, TX
- Active Since 05/05/2008
- Last Updated 09/12/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1760658330
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,062
- DUPIXENT (Biological) $795.57
- TEZSPIRE (Biological) $537.43
- OFEV (Drug) $467.69
- SYMBICORT (Drug) $407.96
- BREZTRI (Drug) $383.52
- FASENRA (Biological) $345.61
- NUCALA (Biological) $325.67
- LONHALA MAGNAIR (Drug) $297.42
- Yupelri (Drug) $287.51
- YUPELRI (Drug) $278.15
- AIRSUPRA (Drug) $248.74
- BEVESPI AEROSPHERE (Drug) $246.53
- NUZYRA (Drug) $214.34
- FASENRA (Drug) $204.60
- AREXVY (Drug) $178.31
- Xyrem (Drug) $168.29
- OPSUMIT (Drug) $151.96
- Esbriet (Biological) $141.38
- ANORO (Drug) $135.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.